Biocryst Pharmaceuticals, Inc. · NASDAQ:BCRX
Biocryst Pharmaceuticals — Q3 2022 Earnings Presentation
6 slides from Biocryst Pharmaceuticals's earnings presentation, Nov 1, 2022
Slide 1: Third Quarter 2022 Results Call
Third Quarter 2022 Results Call Corporate Update & Financial Results November 1, 2022
Slide 2: Forward-Looking Statements
Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain
Slide 3: Agenda
Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ ORLADEYO® (berotralstat) Launch Update: Charlie Gayer – Chief Commercial Officer ◆ Pipeline Update Dr. Helen Thackray – Chief Research and Development Officer ◆ Financial Update Anthony Doyle – Chief Financial Office
Slide 4: Our Pipeline
Our Pipeline EARLY APPROVED / PROGRAM LEAD OPTIMIZATION PRECLINICAL PIVOTAL DEVELOPMENT COMMERCIAL HEREDITARY ANGIOEDEMA (HAE) ORLADEYO® (berotralstat) Oral Plasma Kallikrein Inhibitor COMPLEMENT-MEDIATED DISEASES BCX9930 – Oral Factor D Inhibitor (PNH) BCX9930 – Oral Factor D Inhibitor (C3G/IgAN/PM
Slide 5: Finance Summary
Finance Summary (figures in millions) 3Q22 Cash Position Cash, cash equivalents, restricted cash & investments at September 30, 2021 $204 Cash, cash equivalents, restricted cash & investments at September 30, 2022 $463 Senior Credit Facility A $232 2022 FY Guidance ORLADEYO Revenue $255 Operating Ex
Slide 6: Third Quarter 2022 Results Call
Third Quarter 2022 Results Call Corporate Update & Financial Results November 1, 2022
BioCryst Pharmaceuticals — Q3 2022 Earnings Presentation on 6ix